DOCSLIB.ORG

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 2020 Corporate Social Responsibility Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 2020 Corporate Social Responsibility Report Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 2020 Corporate Social Responsibility Report 癜颁奩眍買 Wu Yifang Chairman and CEO The year of 2020 marked as an extraordinary year. In ghting against coronavirus, full-scales epidemic prevention eorts has been carried out. Being one of active participants, many enterprises spared no eorts in ghting against the virus. Fosun Pharma, as the leading pharmaceutical and healthcare group in China, by comprehensively utilizing its industrial resources and global operational capabilities, respond timely to fulll its social responsibilities as a corporate citizen. Upon outbreak of the pandemic, Fosun Pharma joined hands with Fosun International in allocating medical supplies and resources for frontline treatment. Many doctors and nurses set up as Fosun medical units to the front line. Further, Fosun Pharma independently developed COVID-19 RT-PCR Detection Kit, manufactured and dispatched medical equipment such as ventilators, negative pressure ambulances and mobile CT for sucient supply. Vaccines are recognized as the ultimate means to ght against the pandemic. In search- ing for vaccines, Fosun Pharma decided to cooperate with BioNTech in developing mRNA vaccine, and proactively initiated the develop- ment of mRNA vaccine BNT162b2 in China. Innovation is the most important social responsibility for a pharmaceutical enterprise. In response to unsatised medical demands, Fosun Pharma aims to provide better, more convenient and more aordable products and services for more patients and customers through continuous innovation. We are glad to see that we have achieved outstanding innovation results in 2020. The innovative medicine Artesun® is recommended by WHO for the treatment of severe malaria, which has saved more than 30 million patients in Africa. Till the end of 2020, Fosun Pharma had successfully launched three biosimilars—Han Li Kang®, Han Qu You® and Han Da Yuan®; the new medicine Avatrombopag Maleate tablets (commodity name: Su Ke Xin®) has been approved by China NMPA for launch and included into the national medical insurance reimbursement list. Meanwhile, CAR-T cell therapy product Axicabtagene Ciloleucel injection product was granted priority review for the launch. Quality is the lifeline of a pharmaceutical enterprise. Adhering to the quality principle and concept of “Respect for Life, Focus on Quality, Commitment to Perfection, and Pursuit of Excellence”, we have established the production management and quality system in compli- ance with international standards. Since the launch of operation excellence (FOPEX) in 2017, we have continuously enhanced the internal operation eciency. We continued to implement FOPEX 2.0 system in 2020, achieving good results. In terms of environment, health and safety, we have continuously strengthened investment in environmental protection, and promoted the atmospheric pollution treatment following the concept of sustainable development, in order to reach goals in aspects of energy conservation, emission reduction and environmental protection. As our corporate culture manifested, Self-improvement, Teamwork, Development and Contribution to Society, we always remember to be grateful and give back to the society, and fulll our responsibility as a corporate citizen by supporting social welfare activities such as education, scientic research innovation and healthcare. In the future, adhering to the brand concept of "Innovation for Good Health", Fosun Pharma is committed to enabling every family to enjoy high-quality pharmaceutical products and healthcare services in a sustainable way, to bring good health to families worldwide. Wu Yifang Chairman and CEO of Fosun Pharma 2020 Corporate Social Responsibility Report 3 目 錄 About the Report 06-07 Responsible Employer 62-81 Attracting Talents Through Development Building Our Team Through A Common Cause Key Performance in 2020 08-09 Training Talents Through Their Works Evaluating Talents Through Their Performance • Staff trainings About Fosun Pharma 10-19 • Development of staff An innovation-driven international healthcare industrial • Protection of staff’s safety and health group with business strategically covering the phamaceutical and health industry Responsible Environmental Protection: 82-109 Build environmental-friendly community together • Company profile • Financial performance • EHS strategies and goals • Regulate corporate governance • Climate change risks and responses • Greenhouse gas emissions and energy management Responsible Management: In pursuit of the sustainability 20-29 of talents and products Responsible Community: Innovation for Good Health 110-121 • Fight with the pandemic and overcome the difficult period • Strategies for social responsibilities • Social welfare • Corporate governance • Practice of business ethnics Responsible Operation: Provision of assessable, aordable 30-55 Feedback Form 122 and reliable products and services • Quality first and outstanding operation • Enhance values for clients • Information security and protection of private information Indicator Index 123-136 Responsible Supply Chain: Win-win and sustainable 56-61 business partnership Assurance Statement 137-139 • Supplier management • Green supply chain 4 Innovation for Good Health 目 錄 About the Report 06-07 Responsible Employer 62-81 Attracting Talents Through Development Building Our Team Through A Common Cause Key Performance in 2020 08-09 Training Talents Through Their Works Evaluating Talents Through Their Performance • Staff trainings About Fosun Pharma 10-19 • Development of staff An innovation-driven international healthcare industrial • Protection of staff’s safety and health group with business strategically covering the phamaceutical and health industry Responsible Environmental Protection: 82-109 Build environmental-friendly community together • Company profile • Financial performance • EHS strategies and goals • Regulate corporate governance • Climate change risks and responses • Greenhouse gas emissions and energy management Responsible Management: In pursuit of the sustainability 20-29 of talents and products Responsible Community: Innovation for Good Health 110-121 • Fight with the pandemic and overcome the difficult period • Strategies for social responsibilities • Social welfare • Corporate governance • Practice of business ethnics Responsible Operation: Provision of assessable, aordable 30-55 Feedback Form 122 and reliable products and services • Quality first and outstanding operation • Enhance values for clients • Information security and protection of private information Indicator Index 123-136 Responsible Supply Chain: Win-win and sustainable 56-61 business partnership Assurance Statement 137-139 • Supplier management • Green supply chain 2020 Corporate Social Responsibility Report 5 幬苇香近羔 This is a corporate social responsibility (CSR) report published by Shanghai Fosun Pharmaceutical (Group) Co., Denitions: Ltd. for the thirteenth consecutive year. For the convenience of expression and reading, Fosun Pharma may be referred to, according to the context, as “the This report aims to truthfully present the CSR practice and achievements of the Group to our shareholders, Company”, “Fosun Pharma” or “the Listed Company” in the report; Fosun Pharma and its subsidiaries included in the employees, government agencies, customers and consumers, partners and other stakeholders. consolidated report may be referred to as “the Group”, or “Fosun Pharma Group” ; the wholly-owned subsidiaries of the Fosun Pharma are described as “member enterprises” ; Shanghai Fosun Pharmaceutical Industrial Development Basis of Report: Limited may be referred to as “Fosun Pharmaceutical Industrial Company” or “Industrial Company” . For more description of company names, please refer to the Definitions of enterprise name. This report is in line with the core plan of GRI sustainability reporting standards (GRI Standards) (GRI represents Global Reporting Initiative) and is also in compliance with requirements set out in the ESG Access to the Report: Reporting Guide in Appendix 27 to the Listing Rules issued by the Stock Exchange and is prepared with reference to the national standards on social responsibility (GB/T36000) and the Guidelines on Corporate The report is prepared and printed in simplified Chinese, traditional Chinese and English and is available in both Social Responsibility Reporting for Chinese Enterprises (CASS-CSR 4.0) published by the Corporate Social hardcopy and electronic versions. The latter may be downloaded from the website of Fosun Pharma Responsibility Research Center of School of Economics of Chinese Academy of Social Sciences. (https://www.fosunpharma.com/about/CSR.aspx). In case of any disparity between different versions, the version in simplified Chinese shall prevail. Reporting Period: Report Assurance: 1 January 2020 to 31 December 2020 An external institution has been commissioned by Fosun Pharma to perform third party verification of the Chinese Scope of Report : CSR report and issued an Assurance Statement. The Assurance Statement covers the head office of Fosun Pharma as well as the on-site assurance of pharmaceutical subsidiaries Fosun Long March and Yaneng Bio. The scope of enterprises disclosed in this report is consistent with that of the 2020 Annual Report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Data Description: Please visit the official website of Fosun Pharma (www.fosunpharma.com) for more information on how the Group implements the concepts and
Load more

Recommended publications
  • Your ROC Directors Unanimously Recommend
    11 September 2014 Norton Rose Fulbright Australia ABN 32 720 868 049 Level 15, RACV Tower 485 Bourke Street MELBOURNE VIC 3000 AUSTRALIA Company Announcements Tel +61 3 8686 6000 Australian Securities Exchange Fax +61 3 8686 6505 Level 2 GPO Box 4592, Melbourne VIC 3001 120 King Street MELBOURNE VIC 3000 DX 445 Melbourne nortonrosefulbright.com Direct line +61 3 8686 6710 Email [email protected] Our reference: 2813782 Dear Sir/Madam Proposed takeover bid for all of the ordinary shares in Roc Oil Company Limited We act for a wholly owned subsidiary of Fosun International Limited, Transcendent Resources Limited (Fosun ) in relation to its off-market takeover bid for all of the ordinary shares in Roc Oil Company Limited (ROC ) ( Offer ). On behalf of Fosun, we enclose: (1) a copy of the bidder’s statement dated 11 September 2014 containing the Offer ( Bidder’s Statement ) in accordance with subsection 633(1), item 5 of the Corporations Act 2001 (Cth); and (2) a notice of the date for determining the people to whom information is to be sent in accordance with subsection 633(1), items 6 and 12 of the Corporations Act 2001 (Cth). We note that a copy of the Bidder’s Statement was today sent to the Australian Securities and Investments Commission, and will be sent to ROC today. Yours faithfully James Stewart Partner Norton Rose Fulbright Australia Encl. For personal use only APAC-#24123292-v1 Norton Rose Fulbright Australia is a law firm as defined in the Legal Profession Acts of the Australian states and territory in which it practises.
    [Show full text]
  • Name of Recognized Medical Schools (Foreign)
    1 Name of Recognized Medical Schools (Foreign) Expired AUSTRALIA 1 School of Medicine, Faculty of Heath, University of Tasmania, Tasmania, Australia (5 years Program) 9 Jan Main Affiliated Hospitals 2021 1. Royal H obart Hospital 2. Launceston Gen Hospital 3. NWest Region Hospital 2 Melbourne Medical School, University of Melbourne, Victoria, Australia (4 years Program) 1 Mar Main Affiliated Hospitals 2022 1. St. Vincent’s Public Hospital 2. Epworth Hospital Richmond 3. Austin Health Hospital 4. Bendigo Hospital 5. Western Health (Sunshine, Footscray & Williamstown) 6. Royal Melbourne Hospital Affiliated Hospitals 1. Pater MacCallum Cancer Centre 2. Epworth Hospital Freemasons 3. The Royal Women’s Hospital 4. Mercy Hospital for Women 5. The Northern Hospital 6. Goulburn Valley Health 7. Northeast Health 8. Royal Children’s Hospital 3 School of Medicine and Public Health, University of Newcastle, New South Wales, Australia (5 years Program) 3 May Main Affiliated Hospitals 2022 1.Gosford School 2. John Hunter Hospital Affiliated Hospitals 1. Wyong Hospital 2. Calvary Mater Hospital 3. Belmont Hospital 4. Maitland Hospital 5. Manning Base Hospital & University of Newcastle Department of Rural Health 6. Tamworth Hospital 7. Armidale Hospital 4 Faculty of Medicine, Nursing and Health Sciences, Monash University, Australia (4 and 5 years Program) 8 Nov Main Affiliated Hospitals 1. Eastern Health Clinical School: EHCS 5 Hospitals 2022 2. Southern School for Clinical Sciences: SCS 5 Hospitals 3. Central Clinical School จ ำนวน 6 Hospitals 4. School of Rural Health จ ำนวน 7 Hospital 5 Sydney School of Medicine (Sydney Medical School), Faculty of Medicine and Health, University of Sydney, Australia 12 Dec (4 years Program) 2023 2 Main Affiliated Hospitals 1.
    [Show full text]
  • World Bank Document
    Project No: GXHKY-2008-09-177 Public Disclosure Authorized Nanning Integrated Urban Environment Project Consolidated Executive Assessment Public Disclosure Authorized Summary Report Public Disclosure Authorized Research Academy of Environmental Protection Sciences of Guangxi August 2009 Public Disclosure Authorized NIUEP CEA Summary TABLE OF CONTENTS TABLE OF CONTENTS ABBREVIATIONS ....................................................................................................................... i CURRENCIES & OTHER UNITS ............................................................................................ ii CHEMICAL ABBREVIATIONS ............................................................................................... ii 1 General ........................................................................................................................... - 1 - 1.1 Brief ..................................................................................................................................... - 1 - 1.2 Overall Background of the Environmental Assessment ................................................. - 3 - 1.3 Preparation of CEA ........................................................................................................... - 5 - 2 Project Description ......................................................................................................... - 6 - 2.1 Objectives of the Project .................................................................................................... - 6 - 2.2
    [Show full text]
  • China As a Hybrid Influencer: Non-State Actors As State Proxies COI HYBRID INFLUENCE COI
    Hybrid CoE Research Report 1 JUNE 2021 China as a hybrid influencer: Non-state actors as state proxies COI HYBRID INFLUENCE COI JUKKA AUKIA Hybrid CoE Hybrid CoE Research Report 1 China as a hybrid influencer: Non-state actors as state proxies JUKKA AUKIA 3 Hybrid CoE Research Reports are thorough, in-depth studies providing a deep understanding of hybrid threats and phenomena relating to them. Research Reports build on an original idea and follow academic research report standards, presenting new research findings. They provide either policy-relevant recommendations or practical conclusions. COI Hybrid Influence looks at how state and non-state actors conduct influence activities targeted at Participating States and institutions, as part of a hybrid campaign, and how hostile state actors use their influence tools in ways that attempt to sow instability, or curtail the sovereignty of other nations and the independence of institutions. The focus is on the behaviours, activities, and tools that a hostile actor can use. The goal is to equip practitioners with the tools they need to respond to and deter hybrid threats. COI HI is led by the UK. The European Centre of Excellence for Countering Hybrid Threats tel. +358 400 253 800 www.hybridcoe.fi ISBN (web) 978-952-7282-78-6 ISBN (print) 978-952-7282-79-3 ISSN 2737-0860 June 2021 Hybrid CoE is an international hub for practitioners and experts, building Participating States’ and institutions’ capabilities and enhancing EU-NATO cooperation in countering hybrid threats, located in Helsinki, Finland. The responsibility for the views expressed ultimately rests with the authors.
    [Show full text]
  • Annual Report
    2020 (Incorporated in Hong Kong with limited liability) (Stock Code : 00656) Annual Report Profit Attributable to Owners of the Parent RMB 8,017.9 million Innovation & Win The year 2020 might be the most challenging year for Fosun, yet it was also the best year. After the pandemic, we continue with the “wartime mechanism” and maintain the fighting spirit that we have developed during the global combat against COVID-19. This has resulted in our resilient business performance throughout the year. The pandemic has also allowed us to refine further our capabilities of the Company accumulated over the years for “Industry Operations + Industrial Investment”, FC2M model, globalization and technology innovation. Fosun has thus evolved and become even stronger. The theme of Fosun’s annual report this year is “Innovation & Win”. “Innovation” means Fosun always attaches great importance to innovation. We recognize that we can create world-class products only by increasing investment in innovation and R&D. It is also because of our investment in technology innovation in various industries over the years, as well as leveraging on Fosun’s diversified and globalized business portfolio, the development model of “Industry Operations + Industrial Investment”, and the “wartime” mode that it has upkept since the battle against the pandemic, that together effectively defended the impact brought by the external environment and brought the Group a resilient performance, thereby creating mutually beneficial and win-win situation to all stakeholders. The year 2021 is a new starting point for Fosun’s transformation. Facing the huge opportunities in the industrial internet era, we will continue to create good products and put the operation of customers (C-end) as our top priority to fully unlock the multiplier growth of good products and customer resources in Fosun’s ecosystem.
    [Show full text]
  • Mapping the Accessibility of Medical Facilities of Wuhan During the COVID-19 Pandemic
    International Journal of Geo-Information Article Mapping the Accessibility of Medical Facilities of Wuhan during the COVID-19 Pandemic Zhenqi Zhou 1, Zhen Xu 1,* , Anqi Liu 1, Shuang Zhou 1, Lan Mu 2 and Xuan Zhang 2 1 Department of Landscape Architecture, College of Landscape Architecture, Nanjing Forestry University, Nanjing 210037, China; [email protected] (Z.Z.); [email protected] (A.L.); [email protected] (S.Z.) 2 Department of Geography, University of Georgia, Athens, GA 30602, USA; [email protected] (L.M.); [email protected] (X.Z.) * Correspondence: [email protected] Abstract: In December 2019, the coronavirus disease 2019 (COVID-19) pandemic attacked Wuhan, China. The city government soon strictly locked down the city, implemented a hierarchical diagnosis and treatment system, and took a series of unprecedented pharmaceutical and non-pharmaceutical measures. The residents’ access to the medical resources and the consequently potential demand– supply tension may determine effective diagnosis and treatment, for which travel distance and time are key indicators. Using the Application Programming Interface (API) of Baidu Map, we estimated the travel distance and time from communities to the medical facilities capable of treating COVID-19 patients, and we identified the service areas of those facilities as well. The results showed significant differences in service areas and potential loading across medical facilities. The accessibility of medical facilities in the peripheral areas was inferior to those in the central areas; there was spatial inequality of medical resources within and across districts; the amount of community healthcare Citation: Zhou, Z.; Xu, Z.; Liu, A.; Zhou, S.; Mu, L.; Zhang, X.
    [Show full text]
  • Biontech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
    BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine January 25, 2021 COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) is the first COVID-19 vaccine to receive Authorization for Emergency Use in Hong Kong MAINZ, GERMANY, and SHANGHAI, CHINA, January 25, 2021 —BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “Group”; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of the Hong Kong Special Administrative Region of the PRC (“Hong Kong”), the COVID-19 vaccine COMIRNATY® (also known as BNT162b2, Chinese product name: 復必泰TM) based on BioNTech’s proprietary mRNA technology has received authorization for emergency use in Hong Kong. The vaccine will be produced in BioNTech’s manufacturing facilities in Germany and supplied to Hong Kong for administration under the Hong Kong SAR Government’s COVID-19 Vaccination Program. “We are excited and encouraged that COMIRNATY® has been authorized to emergency use in Hong Kong. This is an important milestone in the joint efforts of BioNTech and Fosun Pharma to achieve vaccine accessibility globally. We will continue working closely with BioNTech to complete the ongoing clinical trial and marketing registration in Greater China,” Wu Yifang, Chairman and CEO of Fosun Pharma said. “We will also cooperate closely with HKSAR regarding vaccination deployment plan to ensure that Hong Kong citizens can receive a well-tolerated and effective mRNA COVID-19 vaccine as soon as possible in order to protect the health of millions of households.” On 16 March 2020, BioNTech and Fosun Pharma announced a strategic collaboration to work jointly on the development and commercialization of a COVID-19 vaccine product in Greater China based on BioNTech’s proprietary mRNA technology platform.
    [Show full text]
  • ACAL China Equity Nov17
    ARETE CAPITAL ASIA CHINA: VALUE IN SELECTED NAMES CHINA EQUITY – OVERVIEW CHINA IS TAKING ITS PLACE ON THE WORLD STAGE • China is a critical player in the world economy and is the worlds largest economy on a purchasing power parity basis. • Xi’s position has been reinforced for the next 5yrs and possibly beyond. The new leadership will retain existing key policies with a focus on economic reform and an emphasis on foreign policy. ECONOMIC TRANSFORMATION WELL UNDERWAY • ‘Smokestack’ industries (coal, aluminium and steel) and ‘providing for populace’ businesses (consumer staples and healthcare) are no longer so dominant and being overtaken by manufacturers and service companies. • In many cases, these new ‘service’ industries are redefining business models in established sectors • The China government has selected and carefully encouraged special policies/industries to have Chinese operations challenge the established order – internally and externally INVESTMENT OPPORTUNITIES EXIST • Amongst the many transformations taking place in China, there are numerous great investment opportunities. We do not recommend an index, but selected stocks • Some of these stocks have made significant gains over the last 12months, but there is still more to come 2 CONTENT OVERVIEW ECONOMY Economy Issues Diversification 4 5 6 Equities Remninbi VALUATIONS 7 8 SITUATIONS MiddlePORTFOLIO Class ecosystem ADVISORY 9 10 SELECTED STOCKS Preferred 11 Valuations 13 3 CHINA – ECONOMY CHINA’s ECONOMIC GROWTH REMAINS RESILIENT … • IMF forecasts (not a leading indicator)
    [Show full text]
  • Table of Codes for Each Court of Each Level
    Table of Codes for Each Court of Each Level Corresponding Type Chinese Court Region Court Name Administrative Name Code Code Area Supreme People’s Court 最高人民法院 最高法 Higher People's Court of 北京市高级人民 Beijing 京 110000 1 Beijing Municipality 法院 Municipality No. 1 Intermediate People's 北京市第一中级 京 01 2 Court of Beijing Municipality 人民法院 Shijingshan Shijingshan District People’s 北京市石景山区 京 0107 110107 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Haidian District of Haidian District People’s 北京市海淀区人 京 0108 110108 Beijing 1 Court of Beijing Municipality 民法院 Municipality Mentougou Mentougou District People’s 北京市门头沟区 京 0109 110109 District of Beijing 1 Court of Beijing Municipality 人民法院 Municipality Changping Changping District People’s 北京市昌平区人 京 0114 110114 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Yanqing County People’s 延庆县人民法院 京 0229 110229 Yanqing County 1 Court No. 2 Intermediate People's 北京市第二中级 京 02 2 Court of Beijing Municipality 人民法院 Dongcheng Dongcheng District People’s 北京市东城区人 京 0101 110101 District of Beijing 1 Court of Beijing Municipality 民法院 Municipality Xicheng District Xicheng District People’s 北京市西城区人 京 0102 110102 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Fengtai District of Fengtai District People’s 北京市丰台区人 京 0106 110106 Beijing 1 Court of Beijing Municipality 民法院 Municipality 1 Fangshan District Fangshan District People’s 北京市房山区人 京 0111 110111 of Beijing 1 Court of Beijing Municipality 民法院 Municipality Daxing District of Daxing District People’s 北京市大兴区人 京 0115
    [Show full text]
  • Evaluation of the Fairness of Urban Lakes' Distribution Based On
    International Journal of Environmental Research and Public Health Article Evaluation of the Fairness of Urban Lakes’ Distribution Based on Spatialization of Population Data: A Case Study of Wuhan Urban Development Zone Jing Wu *, Shen Yang y and Xu Zhang y School of Urban Design, Wuhan University, Wuhan 430072, China; [email protected] (S.Y.); [email protected] (X.Z.) * Correspondence: [email protected] These authors contributed equally to the research. y Received: 14 November 2019; Accepted: 4 December 2019; Published: 8 December 2019 Abstract: Lake reclamation for urban construction has caused serious damage to lakes in cities undergoing rapid urbanization. This process affects urban ecological environment and leads to inconsistent urban expansion, population surge, and uneven distribution of urban lakes. This study measured the fairness of urban lakes’ distribution and explored the spatial matching relationship between service supply and user group demand. The interpretation and analysis of Wuhan’s remote sensing images, population, administrative area, traffic network, and other data in 2018 were used as the basis. Specifically, the spatial distribution pattern and fairness of lakes’ distribution in Wuhan urban development zone were investigated. This study establishes a geographic weighted regression (GWR) model of land cover types and population data based on a spatialization method of population data based on land use, and uses population spatial data and network accessibility analysis results to evaluate lake service levels in the study area. Macroscopically, the correlation analysis of sequence variables and Gini coefficient analysis method are used to measure the fairness of the Wuhan lake distribution problem and equilibrium degree, and the location entropy analysis is used to quantitatively analyze the fairness of lakes and Wuhan streets from the perspective of supply and demand location entropy.
    [Show full text]
  • Anisotropic Patterns of Liver Cancer Prevalence in Guangxi in Southwest China: Is Local Climate a Contributing Factor?
    DOI:http://dx.doi.org/10.7314/APJCP.2015.16.8.3579 Anisotropic Patterns of Liver Cancer Prevalence in Guangxi in Southwest China: Is Local Climate a Contributing Factor? RESEARCH ARTICLE Anisotropic Patterns of Liver Cancer Prevalence in Guangxi in Southwest China: Is Local Climate a Contributing Factor? Wei Deng1&, Long Long2&*, Xian-Yan Tang3, Tian-Ren Huang1, Ji-Lin Li1, Min- Hua Rong1, Ke-Zhi Li1, Hai-Zhou Liu1 Abstract Geographic information system (GIS) technology has useful applications for epidemiology, enabling the detection of spatial patterns of disease dispersion and locating geographic areas at increased risk. In this study, we applied GIS technology to characterize the spatial pattern of mortality due to liver cancer in the autonomous region of Guangxi Zhuang in southwest China. A database with liver cancer mortality data for 1971-1973, 1990-1992, and 2004-2005, including geographic locations and climate conditions, was constructed, and the appropriate associations were investigated. It was found that the regions with the highest mortality rates were central Guangxi with Guigang City at the center, and southwest Guangxi centered in Fusui County. Regions with the lowest mortality rates were eastern Guangxi with Pingnan County at the center, and northern Guangxi centered in Sanjiang and Rongshui counties. Regarding climate conditions, in the 1990s the mortality rate of liver cancer positively correlated with average temperature and average minimum temperature, and negatively correlated with average precipitation. In 2004 through 2005, mortality due to liver cancer positively correlated with the average minimum temperature. Regions of high mortality had lower average humidity and higher average barometric pressure than did regions of low mortality.
    [Show full text]
  • The Research on the Inheritance Value Management of the Fire-Dragon Culture
    2019 3rd International Conference on Education, Management and Social Science (EMSS 2019) The Research on the Inheritance Value Management of the Fire-Dragon Culture Yuan Huang School of Wuhan University of Technology, Hubei 430070, China [email protected] Keywords: Fire-dragon Festival, Value Management, Culture Inheritance Abstract: Different cultural heritages nourish different people, and it is one of the important links between people and society. The long history of the "Fire-dragon Festival" is a folk cultural activity, and its extensive masses enable it to be passed down. In order to explore the inheritance of the artillery culture, we conducted field research and found that the inheritance of the artillery culture appeared crisis. While the relevant laws and regulations are not perfect, the cultural inclusiveness and the cultural connotation are weakened. The study concluded that we should strengthen the traditional culture inheritance Value management, increase the scientific research of the Fire-dragon culture in Binyang, and take the road of folklore protection and nationality inheritance. 1. Introduction China has a history of 5,000 years. Perhaps it is too long and long, which makes our nation not cherish, has too much, and is indifferent to our persistence, customs and complexities, so we unknowingly left the traditional culture, this is the sorrow of our nation. Nowadays, the loss of Chinese traditional culture is serious, and modern people's concern for culture is far from enough. It’s necessary to develop the economy and protect traditional culture meanwhile. Different cultural heritages nourish different people, and it is one of the important links between people and society.
    [Show full text]